Novartis reported Phase III PSMAddition data showing Pluvicto plus standard of care cut the risk of PSA progression by 58% in PSMA-positive metastatic hormone-sensitive prostate cancer. Regulatory decisions in the United States, China and Japan are expected in the second half of 2026.
A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07745361 |
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer |
RECRUITING | PHASE2 |
| NCT07658573 |
AI Multimodal Model for Predicting CRPC Progression Risk |
ACTIVE_NOT_RECRUITING | |
| NCT07641855 |
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07503808 |
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types |
RECRUITING | PHASE1 |
| NCT06966024 |
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers |
RECRUITING | PHASE1 |
| NCT06895811 |
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06378866 |
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial |
RECRUITING | PHASE2 |
| NCT06228404 |
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC |
ACTIVE_NOT_RECRUITING | EARLY_PHASE1 |
| NCT05502315 |
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04549207 |
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer |
ACTIVE_NOT_RECRUITING | PHASE4 |
